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Abstract
Background: Polo-like kinase-1 (PLK-1) is reported to be upregulated in a variety of human
tumors and is implicated in cell proliferation and survival. However, its importance in cervical
carcinoma has not yet been fully elucidated.
Methods:  We examined PLK-1 expression in cervical carcinoma tissues using
immunohistochemical staining. Furthermore, we blocked PLK-1 expression in HeLa cells using
specific siRNA and detected the cell cycle, cell proliferation and chemosensitivity using western
blotting, MTT and flow cytometry.
Results: We provide evidence that expression of PLK-1 exists in human cervical carcinoma tissues
and establish an association with tumor size. Furthermore, we show that PLK-1 knockdown by
transfection of siRNA induces accumulation of HeLa cells in the G2/M cell cycle phase and enhances
cisplatin-induced apoptosis.
Conclusion:  Our results indicate that PLK-1 production in HeLa cells might be critical in
determining whether cells survive or undergo apoptosis. Therefore, targeting PLK-1 might be a
promising strategy for enhancing sensitivity to chemotherapeutic reagents in cervical carcinoma.
Background
Cervical carcinoma is a common malignancy worldwide
and its incidence has been increasing gradually. It poses a
significant health problem, especially in regions such as
Asia and North America. Despite advances in diagnostic
and treatment modalities, the proportion of failed treat-
ments is still significant, with reported rates of 15.6% to
58% [1]. To date, chemotherapy is the mainstay of treat-
ment modalities for cervical carcinoma and cisplatin has
proven to be the most effective single cytotoxic agent for
the treatment of advanced or recurrent cervical cancer [2].
However, the response rate is about 23%, due to chemore-
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sistance. Therefore, it is necessary to develop a novel strat-
egy to overcome the chemoresistance of cervical
carcinoma and improve clinical efficiency and prognosis.
Although the molecular events responsible for the patho-
genesis of cervical carcinoma remain to be elucidated, the
final common pathway of carcinogenesis appears to be a
disruption of the mechanisms involved in the regulation
of cell cycle progression, leading to uncontrolled cell pro-
liferation [3]. Critical cellular signaling underlying the
regulation of cell cycle progression has been implicated in
a number of cancers. With regard to tumorigenesis, it is
worth noting that polo-like kinase 1 (PLK-1), a mitotic
cyclin-independent serine-threonine kinase that is
believed to be involved in the pathogenesis of numerous
carcinomas [4-6], has attracted much attention as a poten-
tial therapeutic target.
PLK-1 is a member of the family of polo-like kinases
involved in a wide variety of cell cycle processes [7]. In
mammalian cells, PLK-1 is primarily localized in the cen-
trosome, where it is responsible for centrosome separa-
tion and maturation. PLK-1-specific antibodies
introduced into HeLa cells by microinjection prevent cen-
trosome separation and reduce γ-tubulin accumulation,
suggesting that PLK-1 functions in regulating centrosome
function [8]. PLK-1 is also a target of the G2 DNA damage
checkpoint, where it undergoes ubiquitin-dependent pro-
teolysis mediated by the checkpoint protein Chfr, impli-
cating the loss of Plk-1 function as an important response
to DNA damage during the G2 phase of the cell cycle [9].
Correspondingly, the elevation of PLK-1 expression
occurs in a broad range of human tumors [10,11], and a
close correlation has been documented between mamma-
lian PLK-1 expression and progression of endometrial and
ovarian cancers [12,13]. Therefore, PLK-1 is implicated as
a critical candidate target for understanding the progres-
sion of cervical carcinoma and improving chemotherapy.
However, little is known about the importance of PLK-1
in the development and management of cervical carci-
noma.
To address this issue, we investigated the expression and
distribution of PLK-1 in cervical carcinoma tissues. Fur-
thermore, in order to determine the importance of PLK-1
in tumor progression, we investigated the effects of PLK-1
knockdown on the biological characteristics of HeLa cells
by taking advantage of small interference RNA (siRNA)
against PLK-1. Our results elucidate the pathogenesis of
cervical carcinoma and may help to develop a novel strat-
egy to improve the efficiency of chemotherapy delivered
to patients with cervical carcinoma.
Materials and methods
Immunohistochemical staining
For immunohistochemical staining, thirty-six surgically
resected human cervical carcinoma tissue samples were
collected from the Department of Obstetrics and Gynecol-
ogy, Wuhan Union Hospital. The study was approved by
the institutional review boards. Immunohistochemical
staining was performed according to our previous proto-
col [14]. Briefly, human tumor tissues were embedded in
paraffin and cut into 5-μm sections that were placed onto
glass slides. After antigen retrieval, sections were stained
for the expression of PLK-1 (BD Biosciences, San Diego,
CA) (1:100)detected by streptavidin-biotin-horseradish
peroxidase complex formation. Tumor sections stained
for IgG instead of primary antibodies were used as the
negative control. The immunoactivities of PLK-1 were
ranked according to the percentage of positive tumor cells:
score 3 (> 75%), score 2 (25-75%), score 1 (< 25%), and
score 0 (negative).
Cell culture, transient transfection, RNA interference, and 
cisplatin treatment
HeLa cells were cultured in RPMI 1640 supplemented
with 10% fetal calf serum (FCS) (Invitrogen, Carlsbad,
CA,). Plasmid construction and transfection were per-
formed as previously described [4]. Briefly, PLK-1 cDNA
was cloned into the pcDNA3.2-DEST vector (Invitrogen),
and the resulting expression plasmid (pcDNA3.2-DEST-
Plk1) was verified according to the reference sequence.
PLK-1 (GenBank accession no. NM_005030) siRNAs, tar-
geting regions of the Plk-1 transcript at positions 362-384,
were also used in this study. HeLa cells were transfected at
70% to 90% confluency using PLK-1 plasmid DNA (up to
4 μg) mixed with Lipofectamine 2000 (Invitrogen) at a
DNA (μg)/lipid (μL) ratio of 1:2.5. Similarly, PLK-1
silencing was performed by transfecting HeLa cells with
PLK-1 siRNA plasmids. At 4-6 h post-transfection, the
plasmid- or siRNA-containing medium was replaced with
normal culture medium containing 10% FCS, and the
cells were incubated in a 5% CO2 incubator at 37°C.
Transfected cells were then cultured in fresh medium for
up to 12-36 h and harvested for gene expression and other
assays. For cisplatin treatment, cisplatin (4 μg/ml) was
added to HeLa cells, with DMSO as control. The time
point chosen for the addition of cisplatin to the trans-
fected cells was 24 h after transfection, and was based on
preliminary experiments (data not shown).
Quantitative RT-PCR analysis for mRNA levels
Real-time RT-PCR was performed as detailed in our previ-
ous report [14]. Briefly, total RNA was extracted with TRI-
zol reagent (Invitrogen), following the manufacturer's
instructions. Reverse transcription (RT) was performed,
and the cDNA was synthesized from 2 μg of total RNA by
using an oligo (dT)18 primer and M-MLV reverse tran-Journal of Experimental & Clinical Cancer Research 2009, 28:130 http://www.jeccr.com/content/28/1/130
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scriptase (TAKARA, Syuzou, Shiga, Japan) for quantitative
PCR. Expression of mRNA was determined using the ABI
PRISM 7300 Detection System (Applied Biosystems, Fos-
ter City, CA) and SYBR Premix Taq™ (TAKARA). The
sequences of the primers were as follows: PLK1
(NM_005030) forward: 5'-GGA CTA TTC GGA CAA GTA
CG-3'; PLK1 reverse: 5'-CGG AAA TAT TTA AGG AGG
GTG A-3'; β-actin (NM_001101) forward: 5'-AAG ATG
ACC CAG ATC ATG TTT GAG ACC-3'; β-actin reverse: 5'-
AGC CAG GTC CAG ACG CAG GAT-3'. The mean value of
the replicates for each sample was calculated and
expressed as cycle threshold (Ct). The amount of gene
expression was then calculated as the difference (ΔCt)
between the Ct value of the target gene and the Ct value of
β-actin.
Assessment of cell viability by MTT Assay
Treated or untreated cells were seeded into 96-well plates
at 1 × 103 cells per well overnight and incubated with dif-
ferent concentrations of cisplatin (0 or 4 μg/ml) per treat-
ment. After culture for 24 h, 20 μl MTT dye solution (5
mg/ml) was added to each well and samples were incu-
bated at 37°C for 4 h. The formazan product was dis-
solved by adding 200 μL of DMSO to each well. The plates
were read at 570 nm.
Immunoblotting analysis
Immunoblotting was performed as previously described
[14]. Briefly, treated and untreated HeLa cells were col-
lected and the protein concentrations of lysates were
determined by the Bradford method (Pierce, Rockford,
IL). Samples containing 10 μg of protein were boiled and
subjected to sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) on 10% Tris-glycine gels and
transferred electrophoretically to polyvinylidene fluoride
membranes. Primary antibodies (mouse anti-human
PLK-1 and β-actin monoclonal antibody, 1:2,000) (Santa
Cruz Biotechnology, Santa Cruz, CA) were used, followed
by incubation with horseradish peroxidase-linked sec-
ondary antibody (goat anti-mouse IgG, 1:1,000). Blots
were visualized using an Enhanced Chemiluminescence
kit (Cell Signaling, Danvers, MA). Therelative band den-
sity of PLK-1 to β-actin was quantified with Bio-Rad
Quantity One 1-D Analysis Software (Bio-Rad, Hercules,
CA). The experiment was performed in triplicate.
Cell cycle and apoptosis analysis by flow cytometry
Cell cycle and apoptosis status of HeLa cells after treat-
ment were determined by flow cytometry. In brief, treated
cells were harvested and washed once with ice-cold 0.1 M
PBS, fixed with 70% ethanol and stained with PI solution
(50 μg/ml propidium iodide, 1 mg/ml RNase). Cells were
then analyzed for cell cycle status by flow cytometry (FAC-
Scan, Becton Dickinson, USA). To quantify apoptosis,
cells were stained with annexin-V and PI using a Vybrant
Apoptosis Assay Kit (Invitrogen) according to the manu-
facturer's instructions.
Hoechst 33258 staining and activity analysis of caspase-3
The morphological alterations associated with apoptosis
were observed in transfected HeLa cells by microscopy
using the Hoechst 33258 staining approach. At 36 h post-
transfection, cells were fixed (methanol/glacial acetic acid
at 3:1) for 15 min at 4°C. Hoechst 33258 (Santa Cruz Bio-
technology, Santa Cruz, CA) was added to the well at a
concentration of 10 μg/ml, and cells were then incubated
for 20 min at 37°C. Before observation, cells were washed
three times with PBS. Caspase-3 activation was also tested
with the Caspase-3 Fluorescent Assay Kit (R&D, Minneap-
olis, MN). Transfected cells were harvested for the assay 36
h after transfection, according to the manual.
Statistical analyses
Immunostaining of tissue sections was analyzed with the
Chi-square test. Differences between groups in terms of
mRNA analysis, cell proliferation, and apoptosis were
analyzed using a two-tailed t-test or analysis of variance
(ANOVA) using SPSS 13.0 software. The significance level
was set at P < 0.05.
Results
Expression of PLK-1 in human cervical carcinoma tissues
To investigate the presence of aberrant PLK-1 expression
in human cervical carcinoma tissues, we examined PLK-1
expression by immunohistochemical staining. The clini-
cal pathologic characteristics of specimens, including
tumor size, lymph node status, tumor grade, distant
metastasis and biomarker expression are listed in Table 1.
Of the 36 tumor sections, 32 showed positive immunos-
taining for PLK-1, with a positive rate of 88.9%. Examples
of immunostained slides are shown in Fig. 1. Cytoplasmic
and some brown nuclear staining in tumor cells served as
an index of PLK-1 expression.
To evaluate the possible importance of PLK-1 in tumor
progression, we then evaluated the relationship between
PLK-1 intensity and tumor size. Using the Spearman rank
correlation test, a statistically significant positive correla-
tion between PLK-1 expression and primary tumor stage
(r = 0.605, P = 0.002) but not metastasis was identified.
Our results, therefore, provided clues that the expression
of PLK-1 is associated with the local expansion of cervical
carcinoma.
Levels of PLK-1 mRNA and protein in HeLa cells after PLK-
1 or siRNA transfection
To evaluate the effects of PLK-1 siRNA on the biological
characteristics of HeLa cells, we first transfected HeLa cells
with the PLK-1 plasmid and PLK-1 siRNA. We harvested
cells at different time points (0 h, 12 h, 24 h and 36 h) toJournal of Experimental & Clinical Cancer Research 2009, 28:130 http://www.jeccr.com/content/28/1/130
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measure PLK-1 gene and protein expression. As illustrated
in Fig 2, levels of PLK-1 mRNA were significantly elevated
after PLK-1 transfection compared to the control cells
transfected with empty plasmid, with an increase in
expression by 2.2-fold at 12 h, 3.5-fold at 24 h, and 4.7-
fold at 36 h (P < 0.05). Similarly, an increase was also
observed in protein level at 24 h (2.1-fold) and 36 h (2.3-
fold). Conversely, siRNA was shown to inhibit PLK-1
mRNA and protein expression. PLK-1 mRNA levels were
significantly reduced after PLK-1 siRNA transfection com-
pared to the control cells transfected with empty plasmid,
with a decrease of 49% at 12 h, 62% at 24 h, 69% at 36 h
(P < 0.05). Similar decreases were also observed at the
protein level at 24 h (58%) and 48 h (76%). Our results
suggest that PLK-1 siRNA transfection into HeLa cells is
able to knock-down the expression of PLK-1.
PLK-1 knock-down by siRNA transfection modulated HeLa 
cell survival
We next evaluated the functional consequences of PLK-1
knock-down on the survival of HeLa cells by morpholog-
ical examination. As illustrated in Fig 3, we observed
enhanced apoptosis in HeLa cells after PLK-1 knock-down
with or without cisplatin treatment, as indicated by typi-
cal nuclear condensation and cellular shrinkage as deter-
mined by Hoechst staining. We then quantitated the
number of condensed nuclei per field for several fields.
The numbers of condensed nuclei in groups A (control),
B (PLK-1), C (PLK-1 siRNA), D (PLK-1 plus cisplatin)
were 2.5 (0-7), 6.2 (0-13), 22.7 (5-65), 35.5 (9-77) (con-
densed nuclei/mm3), respectively; the results were signifi-
cant (P < 0.05).
To determine whether PLK-1 influences HeLa cell survival,
we examined cell cycle characteristics and apoptosis after
PLK-1 knockdown by flow cytometry. As shown in Fig. 4,
we observed that PLK-1 siRNA significantly decreased G1/
S arrest of HeLa cells from 64.5% to 32.5% (P < 0.05).
Conversely, G2/M arrest of HeLa cells increased signifi-
cantly from 34.6% to 67.7% (P < 0.05). These findings
suggested that PLK-1 knockdown contributed to cell cycle
progression. In contrast, PLK-1 transfection significantly
increased G1/S arrest and decreased G2/M arrest in HeLa
cells.
In addition, we also evaluated cell apoptosis after PLK-1
knockdown by double-staining with PI/Annexin-V, fol-
lowed by flow cytometric analysis. We observed a consist-
ent pro-apoptotic effect of PLK-1 knockdown on HeLa
cells. The apoptotic rate of PLK-1 knockdown HeLa cells
increased significantly from 4.2% to 12.5% (P < 0.05),
whereas PLK-1 transfection did not significantly affect
HeLa cell apoptosis (Fig. 4). Interestingly, although cispl-
atin did not drive the cell cycle in combination with PLK-
1 siRNA, it acted synergistically with PLK-1 siRNA in
inducing cell apoptosis (12.5% vs. 24.9%, P < 0.05).
PLK-1 knock-down inhibited cell proliferation and 
increased caspase-3 activity
To further determine the effects of PLK-1 siRNA transfec-
tion on HeLa cells, we then examined cell proliferation
and caspase-3 activity by MTT and fluorescent assay,
respectively. As shown in Fig 5, PLK-1 knockdown signif-
icantly inhibited cell proliferation, as compared to the
control (P < 0.05). However, PLK-1 transfection showed
no significant effect. After treatment with cisplatin, we
observed a synergistic effect of PLK-1 siRNA and cisplatin
treatment on HeLa cell proliferation (P < 0.05). Further-
more, PLK-1 siRNA significantly increased caspase-3 activ-
ity in HeLa cells; caspase-3 activity was further enhanced
by cisplatin compared to control and PLK-1 transfected
HeLa cells (P < 0.05). These results were consistent with
those of the morphological examination, flow cytometric
analysis and proliferation assays, suggesting that PLK-1
knock-down contributes to the induction of apoptosis in
HeLa cells and to enhancing chemosensitivity.
Discussion
It is well-recognized that PLK-1 plays an important role in
cell cycle regulation by functioning in centrosome matu-
ration, spindle formation, mitotic entry, and cytokinesis.
When responding to DNA damage, PLK-1 triggers cell
cycle arrest in the G2 and M phases, determining cell fate.
The significance of PLK-1 has been demonstrated in a vari-
ety of tumors. For example, Takai et al. found that expres-
Table 1: Description of the patient population and PLK-1 
expression.
Characteristic Patients (n = 36)
Age (Median ± SD) 43.2 ± 15.7
Histology
Undifferentiated 21 (58.3%)
Differentiated 15 (41.7%)
Primary tumor stages
T(1) 6 (16.7%)
T(2) 7 (19.5%)
T(3) 9 (25%)
T(4) 14 (38.8%)
Nodular metastasis
Yes 6 (16.7%)
No 30 (83.3%)
Distant metastasis
Yes 3 (8.3%)
No 33 (91.7%)
PLK-1 expression
High (score 3) 17 (47.2%)
Middle (score 2) 8 (22.2%)
Low (score 1) 7 (19.5%)
Negative(score 0) 4 (11.1%)Journal of Experimental & Clinical Cancer Research 2009, 28:130 http://www.jeccr.com/content/28/1/130
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sion of PLK-1 in ovarian cancer is associated with
histological grade and clinical stage [13]. Feng et al.
reported that overexpression of PLK1 is associated with
poor survival due to the inhibition of apoptosis via
enhancement of survivin levels in esophageal squamous
cell carcinoma [15]. PLK-1 has also been demonstrated to
be associated with cancer invasion and metastasis [16,17].
However, the significance of PLK-1 in the pathogenesis
and management of cervical carcinoma is not well-under-
stood. In the present study, we demonstrated, for the first
time, that PLK-1 is expressed in cervical carcinoma with a
positive rate of 88.9%, and PLK-1 expression in tumors
was associated with primary tumor progression (T stage).
Interestingly, we found four samples that were negative
for PLK-1 staining, which were later found to be the differ-
entiated samples. These results suggest that PLK-1 expres-
sion might be associated with the inactivity of cell mitosis.
Therefore, our results indicate that PLK-1 may be a poten-
tial target for tumor evaluation and management of cervi-
cal carcinoma.
PLK is a well-conserved family that has four known mem-
bers in humans: PLK1, PLK2, PLK3, and PLK4 [10]. PLK1
expression is regulated during cell cycle progression. Lev-
els are low in G0, G1, and S, but begin to increase in G2
and peak in M phase. PLK-1 has attracted much attention
in the field of carcinogenesis and cancer therapy due to its
known functions. Blocking PLK-1 through RNA interfer-
ence has shown promise as a way to intervene in cancer
progression [18,19]. RNA interference is a newly discov-
Immunohistochemical staining of PLK-1 in human cervical carcinoma tissues Figure 1
Immunohistochemical staining of PLK-1 in human cervical carcinoma tissues. Representative results of immunos-
taining are presented; cytoplasmic and some nuclear staining can be observed in tumor cells. A, Medium PLK-1 positive staining 
in human cervical carcinoma tissues (original magnification, 200×); B, low PLK-1 positive staining in human cervical carcinoma 
tissues (original magnification, 200×); C, PLK-1 negative control staining in human cervical carcinoma tissues (original magnifica-
tion, 200×); D, Association of PLK-1 expression and primary tumor stage (* P < 0.05 compared to other group).Journal of Experimental & Clinical Cancer Research 2009, 28:130 http://www.jeccr.com/content/28/1/130
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ered cellular pathway for silencing genes in a sequence-
specific manner at the mRNA level through the introduc-
tion of cognate double-stranded small interfering RNA
(siRNA). This method is significantly more efficient than
traditional antisense approaches. In our previous study
[4], we knocked down PLK-1 production in pancreatic
cancer cells by utilizing siRNA transfection, and observed
enhanced chemosensitivity to therapeutic agents. To fur-
ther understand the importance of PLK-1 in the manage-
ment of cervical carcinoma, we used siRNA transfection to
knock down PLK-1 production in HeLa cells.
It has been demonstrated that PLK-1 mRNA expression is
elevated in proliferating cells, such as various cancer cell
lines and tumors of different origins. Here, we observed
the expression of PLK-1 mRNA in HeLa cells. We then
transfected PLK-1 plasmids and PLK-1 siRNA into HeLa
cells, to evaluate the effects of PLK-1 up- or down-regula-
tion on the biological characteristics of HeLa cells. As we
expected, PLK-1 mRNA was significantly elevated after
PLK-1 transfection, compared to the control cells trans-
fected with empty plasmid. In contrast, PLK-1 siRNA sig-
nificantly inhibited PLK-1 production in HeLa cells. These
results showed that siRNA transfection of HeLa cells is
able to knock down the expression of PLK-1. Based on
these findings, we then performed morphological exami-
nations to evaluate the functional consequences of PLK-1
knock-down on HeLa cell survival. We observed enhanced
apoptosis in HeLa cells after PLK-1 knock-down with or
without cisplatin treatment, as indicated by typical
nuclear condensation and cellular shrinkage visualized by
Hoechst staining.
Eukaryotic cells have developed a network of checkpoints
to ensure their survival and the propagation of accurate
copies of the genome to the next generation, even when
suffering from a variety of stresses [19]. PLK-1 is a critical
component responsible for tumor progression. Silencing
Alteration of PLK-1 gene and protein expression in HeLa cells after PLK-1 or siRNA transfection Figure 2
Alteration of PLK-1 gene and protein expression in HeLa cells after PLK-1 or siRNA transfection. PLK-1 produc-
tion in HeLa cells increased after PLK-1 transfection, but was inhibited by siRNA transfection. A, PLK-1 mRNA and protein lev-
els in HeLa cells increased after PLK-1 transfection, but decreased following siRNA transfection. The level of mRNA was 
determined by real-time RT-PCR. A time-dependent induction was observed; B, Representative results of immunoblotting of 
PLK-1 expression in HeLa cells were shown. C, PLK-1 protein in HeLa cells increased after PLK-1 transfection, but decreased 
following siRNA transfection. The level of protein was determined by immunoblotting. A time-dependent modulation was 
observed. Data were the means of three independent experiments. * P < 0.05 compared to the control.Journal of Experimental & Clinical Cancer Research 2009, 28:130 http://www.jeccr.com/content/28/1/130
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PLK1 expression by RNA interference inhibits tumor cell
proliferation and induces G2/M arrest. To determine
whether PLK-1 influences HeLa survival, we examined cell
cycle characteristics and apoptosis after PLK-1 knock-
down by using flow cytometry. Importantly, we observed
that PLK-1 siRNA significantly decreased the G1/S arrest
of HeLa cells from 64.5% to 32.5%. Conversely, G2/M
arrest of HeLa cells increased significantly from 34.6% to
67.7%. These findings suggested that PLK-1 contributes to
HeLa cell cycle progression.
Currently, cervical carcinoma is the second most common
cancer worldwide among women and one of the leading
causes of death in relatively young women. Chemother-
apy represents a crucial strategy for the management of
both primary and recurrent cervical carcinoma [20]. How-
ever, some types of cervical carcinoma exhibit limited sen-
sitivity to cytotoxic agents and easily develop drug
resistance during long-term chemotherapy [21]. For this
reason, enhancing chemosensitivity is essential for
improved prognosis. According to the literature, investi-
gating the importance of PLK-1 in the prevention of other
cancers, we believe PLK-1 can be considered an important
candidate for the enhancement of chemosensitivity in cer-
vical carcinoma.
To examine this possibility, we investigated the apoptosis
of HeLa cells after PLK-1 knockdown by RNA interference.
Importantly, we observed a consistent pro-apoptotic
effect of PLK-1 knock-down in HeLa cells. The apoptotic
rate in HeLa cells increased significantly from 4.2% to
12.5% after PLK-1 knockdown, whereas transfection with
PLK-1 did not affect HeLa cell apoptosis. Although cispla-
tin did not drive the cell cycle, when used in combination
with PLK-1 siRNA, the compound demonstrated a syner-
gistic effect with PLK-1 siRNA in inducing cell apoptosis
(12.5% vs. 24.9%). Consistently, we observed that PLK-1
knockdown significantly inhibited cell proliferation and
PLK-1 knock-down by siRNA transfection modulated apoptosis in HeLa cells Figure 3
PLK-1 knock-down by siRNA transfection modulated apoptosis in HeLa cells. A, Control; B, Cells transfected with 
PLK-1; C, Cells transfected with PLK-1 siRNA; D, Cells transfected with PLK-1 siRNA and treated with cisplatin (4 μg/ml) 
(original magnification, 200×); Enhanced apoptosis was demonstrated in B, C and D by typical nuclear condensation after 
siRNA transfection, as determined by Hoechst staining. Three independent experiments were performed. Representative fluo-
rescent images are presented.Journal of Experimental & Clinical Cancer Research 2009, 28:130 http://www.jeccr.com/content/28/1/130
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PLK-1 knock-down modulated cell cycle characteristics and apoptosis in cisplatin-treated HeLa cells Figure 4
PLK-1 knock-down modulated cell cycle characteristics and apoptosis in cisplatin-treated HeLa cells. A synergis-
tic effect with cisplatin treatment (4 μg/ml) was demonstrated. A, PLK-1 siRNA significantly decreased G1/S arrest but 
enhanced G2/M arrest of HeLa cells; B, PLK-1 siRNA significantly enhanced the apoptosis of HeLa cells, demonstrating a syner-
gistic effect with cisplatin treatment. Representative results of flow cytometric analysis are presented. Data were the means of 
three independent experiments. * P < 0.05, compared to the control cells transfected with empty plasmid; ** P < 0.05, com-
pared to the cells transfected with PLK-1 siRNA alone.Journal of Experimental & Clinical Cancer Research 2009, 28:130 http://www.jeccr.com/content/28/1/130
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induced apoptosis, displaying a synergistic effect with cis-
platin treatment. Based on these results, PLK-1 knock-
down shows promise as an adjuvant chemotherapy for
cervical carcinoma. It will be of great interest to further
investigate the possible mechanisms underlying PLK-1-
driven cell survival.
In conclusion, we have provided evidence that there is a
correlation between overexpressed PLK-1 and the primary
cancer stage in cervical carcinoma tissues. To further char-
acterize the role of PLK-1 in the carcinogenesis of cervical
carcinoma and the importance of PLK-1 knockdown in
the prevention of cervical carcinoma, we investigated the
effects of PLK-1 RNA interference on cell cycle characteris-
tics and apoptosis in HeLa cells. We demonstrated that
PLK-1 knockdown contributed to G2/M arrest and to the
induction of apoptosis in HeLa cells, as well as to the inhi-
bition of cell viability and to the enhancement of chemo-
sensitivity. Therefore, PLK-1 can be thought of as a
potential target for preventing cervical carcinoma.
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